Preoperative chemotherapy for prostatic stromal invasive urothelial bladder cancer: comparison of oncological outcomes of male patients with cT4a disease undergoing radical cystectomy with or without preoperative chemotherapy

References

• Shen SS, Lerner SP, Muezzinoglu B, et al. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006;37:726–734.
   PubMed Web of Science ®Google Scholar
• Donat SM, Genega EM, Herr HW, et al. Mechanisms of prostatic stromal invasion in patients with bladder cancer: clinical significance. J Urol. 2001;165:1117–1120.
   PubMed Web of Science ®Google Scholar
• Palou J, Wood D, Bochner BH, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: urothelial carcinoma of the prostate. Eur Urol. 2013;63:81–87.
   PubMed Web of Science ®Google Scholar
• Ayyathurai R, Gomez P, Luongo T, et al. Prostatic involvement by urothelial carcinoma of the bladder: clinicopathological features and outcome after radical cystectomy. BJU Int. 2007;100:1021–1025.
   PubMed Web of Science ®Google Scholar
• Barocas DA, Patel SG, Chang SS, et al. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. BJU Int. 2009;104:1091–1097.
   PubMed Web of Science ®Google Scholar
• Esrig D, Freeman JA, Elmajian DA, et al. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol. 1996;156:1071–1076.
   PubMed Web of Science ®Google Scholar
• Gakis G, Efstathiou J, Lerner SP, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63:45–57.
   PubMed Web of Science ®Google Scholar
• Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011;59:1009–1018.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Compérat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65:778–792.
   PubMed Web of Science ®Google Scholar
• Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–866.
   PubMed Web of Science ®Google Scholar
• Griffiths G, Hall R, Sylvester R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171–2177.
   PubMed Web of Science ®Google Scholar
• Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003;361:1927–1934.
   PubMed Web of Science ®Google Scholar
• Winquist E, Kirchner T, Segal R, et al. Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence based Care Practice Guidelines Initiative. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004;171:561–569.
   PubMed Web of Science ®Google Scholar
• Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 2005;48:202–205.
   PubMed Web of Science ®Google Scholar
• Zargar-Shoshtari K, Zargar H, Lotan Y, et al. A multi-institutional analysis of outcomes of patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy. J Urol. 2016;195:53–59.
   PubMed Web of Science ®Google Scholar
• Fairey AS, Daneshmand S, Quinn D, et al. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Urol Oncol. 2013;31:1737–1743.
   PubMed Web of Science ®Google Scholar
• American Joint Committee on Cancer. Urinary bladder. In: Fleming ID, Cooper JS, Henson DE, et al. editors. AJCC cancer staging manual. 5th ed. Philadelphia (PA): Lippincott-Raven; 1997.
   Google Scholar
• Scosyrev E, Messing EM, van Wijngaarden E, et al. Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer 2012;118:72–81.
   PubMed Web of Science ®Google Scholar
• Zargar H, Espiritu PN, Fairey AS, et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015;67:241–249.
   PubMed Web of Science ®Google Scholar
• Hermans TJ, Fransen van de Putte EE, Horenblas S, et al. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-results of a nationwide population-based study. Eur J Cancer. 2016;69:1–8.
   PubMed Web of Science ®Google Scholar
• Stanik M, Poprach A, Macik D, et al. Clinically node-positive bladder cancer: oncological results of induction chemotherapy and consolidative surgery. Neoplasma 2018;65:287–291.
   PubMed Web of Science ®Google Scholar
• Meijer RP, Mertens LS, van Rhijn BW, et al. Induction chemotherapy followed by surgery in node positive bladder cancer. Urology 2014;83:134–139.
   PubMed Web of Science ®Google Scholar
• Svatek RS, Shariat SF, Novara G, et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int. 2011;107:898–904.
   PubMed Web of Science ®Google Scholar
• Moschini M, Luzzago S, Zaffuto E, et al. The surgical management of patients with clinical stage T4 bladder cancer: a single institution experience. Eur J Surg Oncol.2017;43:808–814.
   PubMed Web of Science ®Google Scholar
• Brant A, Kates M, Chappidi MR, et al. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: is therapeutic effect owing to chemotherapy or TURBT? Urol Oncol. 2017;35:34.e17–34.e25.
   Web of Science ®Google Scholar
• Nielsen ME, Bastian PJ, Palapattu GS, et al. Recurrence-free survival after radical cystectomy of patients downstaged by transurethral resection. Urology 2007;70:1091–1095.
   PubMed Web of Science ®Google Scholar
• Tollefson MK, Boorjian SA, Farmer SA, et al. Downstaging to non-invasive urothelial carcinoma is associated with improved outcome following radical cystectomy for patients with cT2 disease. World J Urol. 2012;30:795–799.
   PubMed Web of Science ®Google Scholar
• Nagele U, Anastasiadis A, Merseburger A, et al. The rationale for radical cystectomy as primary therapy for T4 bladder cancer. World J Urol. 2007;25:401–405.
   PubMed Web of Science ®Google Scholar
• Nagele U, Anastasiadis AG, Merseburger AS, et al. Surgical approach in patients with T4 bladder cancer as primary treatment: disaster or option with improved quality of life. Indian J Urol. 2008;24:95–98.
   PubMedGoogle Scholar
• Skinner D, Stein J, Lieskovsky G, et al. 25-year experience in the management of invasive bladder cancer by radical cystectomy. Eur Urol. 1998;33 Suppl 4:25–26.
   PubMed Web of Science ®Google Scholar
• Streeper N, Simons C, Konety B, et al. The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer. BJU Int. 2009;103:475–479.
   PubMed Web of Science ®Google Scholar